Thrombosis
News
FDA again rejects rivaroxaban for ACS
For a second time, the FDA has decided against approving rivaroxaban (Xarelto) to reduce the risk of cardiovascular events in patients with acute...
News
Dabigatran noninferior to warfarin for preventing recurrent VTE
New research suggests dabigatran is noninferior to warfarin as extended prophylaxis for recurrent venous thromboembolism (VTE), and warfarin...
News
New antihemophilic factors last longer than standard treatments
Data from the phase 3 A-LONG study indicated that patients with hemophilia A could maintain low bleeding rates with once- to twice-weekly...
News
FDA approves plasma product
The FDA has approved a pooled plasma blood product (Octaplas) that can be used to replace coagulation factors in patients with certain medical...
News
FDA approves apixaban for patients with NVAF
The agency’s decision is based on results of the ARISTOTLE trial, in which NVAF patients taking apixaban experienced fewer strokes than those on...
News
Study supports extended apixaban use
ATLANTA—Due to results of the AMPLIFY-EXTENSION study, researchers are recommending a new indication for apixaban: long-term use to prevent...
News
Factor appears safe, effective in hemophilia B
The goal of the phase 3 study, called B-LONG, was to evaluate the safety and efficacy of a long-lasting recombinant factor IX Fc fusion protein (...
News
Secondary prophylaxis reduces bleeding in hemophilia
PARIS—Results of a phase 3 study indicate that the recombinant antihemophilic factor octocog alfa is effective as secondary bleeding prophylaxis...
News
Hemophilia patients plagued by professional challenges
their disorder has had a negative impact on their career. In fact, 1 in 5 patients said they have lost a job because of their condition....
News
Drug for aHUS effective but expensive
AMSTERDAM—Eculizumab elicits “phenomenal” results in atypical hemolytic uremic syndrome (aHUS), according to two presentations given at the 17th...